BI 1206 companion diagnostic - SkylineDx
Latest Information Update: 28 Apr 2023
At a glance
- Originator SkylineDx
- Developer BioInvent International; SkylineDx
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in Non-Hodgkin's-lymphoma(Diagnosis) in Netherlands
- 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(Diagnosis) in Netherlands
- 28 Apr 2020 BioInvent and SkylineDx conclude agreement for co-development of BI 1206 companion diagnostic for Non-Hodgkin's lymphoma and Solid tumours